Nasal Chlorogenic Acid Composition for Brain Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chlorogenic acid has low bioavailability and nasal absorption rate due to its molecular structure, limiting its effectiveness in oral administration and requiring injection-based drug development, with no effective nasal formulations available for anti-tumor treatments beyond allergic rhinitis.
Innovation Solution
A nasal composition containing chlorogenic acid with pharmaceutically acceptable excipients such as adhesives and absorption enhancers, formulated as nasal powders, aerosols, or sprays, which improve bioavailability and penetration through the blood-brain barrier for anti-tumor treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If chlorogenic acid is administered orally, then the administration method is simple and compliance is good, but the bioavailability is low due to molecular structure degradation
Solution Approach 1:
The patent uses absorption enhancers (such as cyclodextrin, lecithin, or cholic acid sodium) as intermediary substances to facilitate the absorption of chlorogenic acid through the nasal mucosa. These mediators form inclusion complexes or micelles with chlorogenic acid, protecting it from degradation and enhancing its permeability across the nasal epithelial barrier, thereby resolving the contradiction between simple administration and low bioavailability.
Solution Approach 2:
The patent changes the physical and chemical parameters of chlorogenic acid delivery by formulating it as nasal powder, aerosol, or spray with specific particle sizes (20-100 μm for powder) and using various excipients. These parameter changes in formulation state and physical form enable the drug to bypass first-pass metabolism and achieve high bioavailability through nasal mucosal absorption while maintaining simple administration.
2Reliability
If chlorogenic acid is administered via injection, then the bioavailability is high, but the administration method is complex and requires medical intervention
Solution Approach 1:
The patent employs absorption enhancers as mediators to achieve injection-level bioavailability through non-invasive nasal administration. The enhancers (cyclodextrin, lecithin, cholic acid sodium) create favorable microenvironment conditions for drug absorption, allowing chlorogenic acid to reach systemic circulation efficiently without requiring injection, thus eliminating the need for medical intervention while maintaining high bioavailability.
Solution Approach 2:
The patent transitions from parenteral (injection) to mucosal (nasal) administration route, changing the dimension of drug delivery from systemic direct introduction to localized mucosal absorption. This dimensional change in administration route, combined with absorption enhancement technology, achieves comparable bioavailability to injection while dramatically improving ease of operation and patient compliance.
3Ease of manufacture
If simple nasal powder formulation is used, then the formula is simple to prepare, but the nasal absorption rate is low and it can only treat allergic rhinitis
Solution Approach 1:
The patent introduces absorption enhancers (cyclodextrin, lecithin, or cholic acid sodium) as intermediary substances in the nasal powder formulation. These enhancers form inclusion complexes or micellar structures with chlorogenic acid, significantly improving its solubility and permeability through the nasal mucosa. This allows the simple powder formulation to achieve high absorption rates suitable for anti-tumor treatment, not just allergic rhinitis.
Solution Approach 2:
The patent creates composite nasal powder formulations combining chlorogenic acid with absorption enhancers and other excipients (adhesives, disintegrants). This composite material approach maintains formulation simplicity while achieving enhanced nasal absorption through the synergistic effects of the components, enabling anti-tumor therapeutic applications.
4Reliability
If absorption enhancers and adhesives are added to nasal powder, then the nasal absorption rate improves, but the formulation complexity increases
Solution Approach 1:
The patent optimizes the parameters of formulation complexity by controlling the particle size (20-100 μm) and specifying precise ratios of components (10-90 parts chlorogenic acid, 5-80 parts adhesive, 0-70 parts absorption enhancer). These parameter specifications enable standardized manufacturing processes and quality control, making the enhanced formulation as manageable as simple formulations despite the added functional components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition significantly enhances the bioavailability and efficacy of chlorogenic acid for nasal administration, effectively treating brain tumors and nasopharyngeal carcinoma, with aerosols demonstrating the highest blood-brain barrier permeability and tumor inhibition rates comparable to intravenous injections.
Implementation Method 1
the excipients of said nasal powder are adhesive and absorption enhancer
Implementation Method 2
it can also be absorbed through the nasal mucosa into the systemic circulation and reach the brain
Data Source
AI summary
An anti-tumor composition for nasal administration has chlorogenic acid as an active ingredient, with the addition of pharmaceutically acceptable excipients or auxiliary ingredients. The chlorogenic acid preparation can improve the bioavailability of chlorogenic acid for nasal administration, penetrate the blood-brain barrier, have a significant inhibitory effect on brain tumors and nasopharyngeal carcinoma, and possess a clinical application value.